Estradiol valerate/methenmadinone caproate

Estradiol valerate /
methenmadinone caproate
	Estradiol valerate (top) and; methenmadinone caproate (bottom)
Combination of
Estradiol valerate	Estrogen
Methenmadinone caproate	Progestogen
Clinical data
Other names	EV/MMC; Lutofollin
Routes of; administration	Intramuscular injection
Identifiers
CAS Number	61829-06-9;

Estradiol valerate/methenmadinone caproate (EV/MMC), known by the tentative brand name Lutofollin, is a combination medication of estradiol valerate (EV), an estrogen, and methenmadinone caproate (MMC; superlutin caproate), a progestin, which was developed for potential use as a once-a-month combined injectable contraceptive but was never marketed.^[1]^[2]^[3] It contained 10 mg EV and 60 mg MMC in 1 mL oil solution and was intended for administration by intramuscular injection once every 4 weeks.^[1]^[2]^[3]

References[edit]

^ ^a ^b Stĕrba R (January 1976). "Tschechoslowakisches Injektionskontrazeptivum, einmal im Monat zu verabreichen" [A Czechoslovak injection-contraceptive agent administered once a month]. Zentralblatt für Gynakologie (in German). 98 (3): 158–160. ISSN 0044-4197. PMID 970015.
^ ^a ^b Mokhtar K. Toppozada (1983), Monthly Injectable Contraceptives
^ ^a ^b Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.